Omega Therapeutics Company Overview

Omega Therapeutics logo
Omega Therapeutics
Omega Therapeutics primary media

About Omega Therapeutics

Omega Therapeutics (NASDAQ:OMGA) specializes in harnessing the power of genomic programming to develop a new class of DNA-sequence-targeting, mRNA-expressing therapies with the objective of revolutionizing the treatment across multiple disease areas. Their projects primarily focus on leveraging their proprietary Omega Epigenomic Programming™ platform to precisely tune gene expression, without altering the native DNA sequence, facilitating the development of therapies aimed at a broad range of diseases including oncology, regenerative medicine, and autoimmune diseases. Omega aims to pioneer a new era of genomic medicine, with the goal of unlocking the full potential of the human genome to conquer diseases at their genetic roots.

What is Omega Therapeutics known for?

Snapshot

2016
Year founded
94
Employees
Cambridge, United States
Head office
Loading Map...

Operations

All Locations
Newton, US

Products and/or services of Omega Therapeutics

  • OTX-2002, a programmable epigenetic mRNA therapy targeting the MYC oncogene for hepatocellular carcinoma.
  • OTX-2101, addressing solid tumors through epigenetic modulation.
  • Development of a platform for modularly programming or reprogramming gene expression without altering the DNA sequence.
  • Partnerships aimed at expanding the application of epigenetic therapy across various diseases.

Omega Therapeutics executive team

  • Dr. Kaan Certel Ph.D.President, CEO & Director
  • Dr. David A. Berry M.D., Ph.D.Founder
  • Ms. Barbara Y. Chan CPAPrincipal Financial Office, Principal Accounting Officer & Chief Accounting Officer
  • Dr. Jennifer Nelson Ph.D.Chief Scientific Officer
  • Ms. Eva StroynowskiSenior Vice President of Investor Relations & Corporate Affairs
  • Mr. Anthony MullinChief People Officer
  • Mr. Charles O'Donnell Ph.D.VP and Head of Computational Genomics & Data Sciences
  • Dr. Joe Newman Ph.D.Senior Vice President of Early Discovery

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.